Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803945 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease
A Phase 1 study, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01803945 is a Phase 1 study that was terminated before completion, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 32 participants.
The verdict
NCT01803945, a Phase 1 study, was terminated before completion, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of orally administered AVE8112 in patients with Parkinson's Disease (PD).
Interventions
- DRUG Placebo
- DRUG AVE8112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01803945
The ClinicalTrials.gov registry entry for NCT01803945 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01803945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01803945 about?
NCT01803945 is a clinical study titled "A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease". This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of orally administered AVE8112 in patients with Parkinson's Disease (PD).
What is the current status of trial NCT01803945?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01803945?
The interventions under investigation include: Placebo (DRUG), AVE8112 (DRUG).
Who is sponsoring clinical trial NCT01803945?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.